EGFR and non-small cell lung carcinoma: 8.2.Amivantamab indications published in EMA Data Sheet not funded by SNS in Spain:EMA indication #1: Amivantamab monotherapy is indicated for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of a platinum-based therapy [60].Clinical evidence approval EMA indication #1: Phase I/II CHRYSALIS, multicenter, open label, multicohort study conducted to assess the safety and efficacy of amivantamab in patients with locally advanced or metastatic NSCLC.